From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
Short-term efficacy
Number of patients (Percent)
Complete response (CR)
0 (0)
Partial response (PR)
Stable disease (SD)
2 (66.7)
Progressive disease (PD)
1 (33.3)